SETEVRI Trademark

Trademark Overview

On Monday, June 3, 2024, a trademark application was filed for SETEVRI with the United States Patent and Trademark Office. The USPTO has given the SETEVRI trademark a serial number of 79400277. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Monday, September 2, 2024. This trademark is owned by DAIICHI SANKYO COMPANY, LIMITED. The SETEVRI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of cancer, oncological diseases, leukemia, pseudoxanthoma, systemic lupus erythematosus, cardiovascular diseases, kidney diseases, Netherton syndrome.
setevri

General Information

Serial Number79400277
Word MarkSETEVRI
Filing DateMonday, June 3, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateMonday, September 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment and prevention of cancer, oncological diseases, leukemia, pseudoxanthoma, systemic lupus erythematosus, cardiovascular diseases, kidney diseases, Netherton syndrome.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 25, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDAIICHI SANKYO COMPANY, LIMITED
Party Type10 - Original Applicant
Legal Entity Type98 - Unknown
AddressJP

Trademark Events

Event DateEvent Description
Thursday, July 18, 2024SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Thursday, July 25, 2024LIMITATION FROM ORIGINAL APPLICATION ENTERED
Friday, July 26, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 26, 2024APPLICATION FILING RECEIPT MAILED
Thursday, August 22, 2024ASSIGNED TO EXAMINER
Friday, August 30, 2024NON-FINAL ACTION WRITTEN
Saturday, August 31, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, September 2, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, September 2, 2024REFUSAL PROCESSED BY MPU
Monday, September 30, 2024REFUSAL PROCESSED BY IB

Related Keywords

setevri diseases erythematosus lupus cardiovascular kidney syndrome netherton systemic leukemia treatment